This tutorial gives an overview of how radionuclide therapy in nuclear medicine is involved in palliation of bony metastases.
After completing this tutorial, attendees will be able to list the most important characteristics of therapies used in palliation of bony metastases.
This tutorial is designed to provide the viewer with a comprehensive overview of Radionuclide Therapy for the purpose of palliating pain caused by bony metastases. This is a very valuable, but very under-utilized procedure that renders pain relief (sometimes complete) in ~80% of all patients treated with the available therapeutic radiopharmaceuticals.
This tutorial covers a historical overview of palliation of pain with therapeutic radiopharmaceuticals
A description of these radiopharmaceuticals and the physical properties of the associated β- emitting radionuclide as well as typical recommended doses
The epidemiology of cancer resulting in pain from metastases, especially breast and prostate cancer
All the therapeutic approaches utilized for palliating bone pain, with special emphasis on radiopharmaceuticals
Eligibility criteria for undergoing the study
Internal radiation dosimetry of each available drug
Typical clinical outcomes
Very detailed information about clinical use of each of the three available drugs.
OBJECTIVES: At the conclusion of this presentation, attendees should be able to
• List the three therapeutic radiopharmaceuticals available for palliation of pain from bony metastases and give their typical administered doses and the mode of decay and half-life of each of the radiopharmaceuticals
• Discuss the demographics of breast and prostate cancer and the expected clinical outcomes following administration of each of these drugs
• List other therapeutic approaches for palliation of pain that do not involve use of radioactivity and the limitations of each
• List at least three eligibility criteria for undergoing this type of radionuclide therapy
• Compare the whole body and bone marrow internal radiation doses for each of the three available radiopharmaceuticals. |